Imipenem Cilastatin Panpharma

Imipenem, the active ingredient in Imipenem Cilastatin Panpharma, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary tract, skin, respiratory and febrile neutropenia, in hospitalized patients. It is administered under medical supervision and is indicated for infections caused by susceptible Gram‑negative and Gram‑positive organisms.

GNH USA supplies Imipenem Cilastatin Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing regulatory‑approved documentation, reliable logistics and responsive technical support to meet global healthcare needs.

Imipenem/cilastatin is a carbapenem antibiotic used to treat serious bacterial infections.

- Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens to resolve infection. - Complicated urinary tract infections: eliminates resistant Gram‑negative organisms causing pyelonephritis. - Skin and soft‑tissue infections: provides broad‑spectrum coverage for severe cellulitis and abscesses. - Lower respiratory tract infections (including pneumonia): treats hospital‑acquired and ventilator‑associated pneumonia. - Febrile neutropenia: offers rapid bacterial clearance in immunocompromised patients.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: may be watery or loose. - Headache: transient cranial discomfort. - Rash: erythematous skin eruption. - Elevated liver enzymes: mild hepatic enzyme rise. - Injection site pain: local discomfort during administration.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated diarrhea: severe colitis. - Severe neutropenia: marked reduction in white blood cells. - Stevens‑Johnson syndrome: extensive skin and mucosal detachment. - Renal dysfunction: acute kidney injury in susceptible individuals.

Use of imipenem/cilastatin requires careful clinical assessment.

- Assess renal function: dose adjustment may be needed in impaired kidneys. - Monitor for seizures: especially in patients with CNS disorders. - Evaluate hypersensitivity: discontinue if anaphylactic signs appear. - Use cautiously in patients with a history of seizures or epilepsy. - Adjust dose in renal impairment: follow prescriber guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/cilastatin can interact with several medicines.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - Ganciclovir: concurrent use may lower ganciclovir concentrations. - Probenecid: may increase imipenem toxicity by reducing renal clearance.

Moderate Interactions (Monitor Closely): - Diuretics: combined use can exacerbate electrolyte disturbances. - NSAIDs: may increase risk of renal impairment. - Other nephrotoxic agents: monitor kidney function closely. - Anticoagulants: potential alteration of INR, require monitoring.